Word: chronically
(lookup in dictionary)
(lookup stats)
Dates: all
Sort By: most recent first
(reverse)
...compared epibatidine with several hundred related compounds they had synthesized as experimental treatments for Alzheimer's disease. One of them, ABT-594, turned out to be remarkably similar but much less toxic. Tests on animals indicate that ABT-594 is about 50 times better than morphine in relieving both chronic and acute pain yet seems to be nonaddictive. Phase II tests on humans should be completed by the end of the year...
Each species of cone snail produces a unique venom that contains between 50 and 200 pharmacologically active peptides known as conotoxins. The most advanced conotoxin-derived drug in development is Elan Corp.'s Ziconotide, a nonaddictive treatment for severe chronic pain that is awaiting FDA approval. Cognetix, based in Salt Lake City, Utah, recently started clinical trials on a possible epilepsy treatment. Also in the works: potential therapies for schizophrenia, stroke and Parkinson's and Alzheimer's diseases...
...group of more than 40 disorders that arise when the immune system launches a sustained attack against the body. Ailments as diverse as psoriasis, multiple sclerosis and Type I diabetes are all caused by an immune system run amuck. No one knows what initiates any of these chronic diseases or how they might be cured, but researchers have lately made significant headway in developing drugs to treat them--drugs that arguably represent the first substantial advancement in the field in 50 years...
...diseases. Steroids, for example--a mainstay of lupus therapy--shut down the immune system and suppress inflammation, but they can also promote hardening of the arteries, bone loss, obesity and even psychosis. Steroids are, in fact, among the leading causes of death and morbidity for patients with chronic lupus...
Many of the new therapies also happen to be incredibly potent. Last month, for example, pharmaceutical giant Novartis reported spectacular results in a clinical trial of Glivec, a drug that disables a uniquely aberrant protein produced inside cells of chronic myelogenous leukemia, which afflicts 4,400 new patients in the U.S. each year. In the drug's very first test, every patient went into remission. In the most recent results, 30% showed no sign of the chromosomal damage that marks the disease and appeared to have been cured. "This drug is amazing," says Richard Stone, an oncologist at the Dana...